ArticleFrontiers in oncology2025
Transcriptome analyses identify 10 deregulated hub genes and essential molecular mechanisms in early-onset colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of Systems Genetics to Investigate Molecular Pathology of Early-Onset Colorectal Cancer.Chemical biology & drug design · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The rapid increase in early-onset colorectal cancer (EoCRC) case numbers in recent years indicated an urgent need to identify the essential mechanisms and markers for EoCRC diagnosis and treatment. Therefore, this study aimed to analyze the metadata to overcome the limitation of the sample number of previous EoCRC research and to identify central mechanisms and genes that are crucial for EoCRC. Methods: This study employed statistical analysis of data from the cBioPortal and GEPIA databases to identify overexpressed EoCRC genes. Using a protein-protein interaction map, it identified hub genes. The function of these genes was clarified via risk model, survival, and cell model analysis. Results and Discussion: The results of clinical data analysis showed an increased rate of late-stage diagnosis and a lower overall survival of the EoCRC cohort. A total of 953 enriched gene samples were detected in EoCRC and 89 genes were identified as EoCRC overexpression genes. From the protein-protein interactions among 53 genes, the top 10 hub genes showed potential for EoCRC diagnosis and prognosis by linking gene expression to diagnosis and survival analysis data. The knockdown of four selected hub genes in the cell model identified the association of EoCRC overexpression hub genes with tumor development and suggested their role in mTOR signaling, cell cycle, and apoptosis regulation. In summary, the study analyzed molecular and clinical data to identify hub genes associated with cancer prognosis in patients with EoCRC. These genes may serve as targets for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.